Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS

Zimmermann, Maria; Sanderson, Nicholas S R; Rasenack, Maria; Lalive d'Epinay, Patrice; Lang, Alois B; Curtin, François; Lindberg, Raija L P; Kappos, Ludwig; Derfuss, Tobias

doi:10.1212/NXI.0000000000000144

Scientific article

English

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS

ContributorsZimmermann, Maria; Sanderson, Nicholas S R; Rasenack, Maria; Lalive d'Epinay, Patrice; Lang, Alois B; Curtin, François; Lindberg, Raija L P; Kappos, Ludwig; Derfuss, Tobias

Published inNeurology® neuroimmunology & neuroinflammation, vol. 2, no. 5, e144

Publication date2015

Abstract

To monitor the systemic immune responses of patients with multiple sclerosis (MS) under treatment with GNbAC1, a monoclonal antibody against the envelope protein of the MS- associated retrovirus, during a phase 2a trial.

Affiliation

Faculté de médecine / Section de médecine clinique / Département des neurosciences cliniques

Research group

Scléroses en plaques, neuroimmunologie, encéphalite autoimmune expérimentale (843)

Citation (ISO format)

ZIMMERMANN, Maria et al. Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS. In: Neurology® neuroimmunology & neuroinflammation, 2015, vol. 2, n° 5, p. e144. doi: 10.1212/NXI.0000000000000144

Article (Published version)

Identifiers

PID : unige:89955
DOI : 10.1212/NXI.0000000000000144
PMID : 26380353

ISSN of the journal2332-7812

412views

0downloads

Creation11/30/2016 2:42:00 PM

First validation11/30/2016 2:42:00 PM

Update time03/15/2023 1:06:00 AM

Status update03/15/2023 1:06:00 AM

Last indexation01/16/2024 10:36:35 PM

Archive ouverte UNIGE

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS

To monitor the systemic immune responses of patients with multiple sclerosis (MS) under treatment with GNbAC1, a monoclonal antibody against the envelope protein of the MS- associated retrovirus, during a phase 2a trial.

Technical informations